The study library of Defiance International, a supplier of chemical sequences for research use, carries each record’s verification state and its authors’ citation; the findings are theirs, not ours.
Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.
Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.
Defiance International, a supplier of chemical sequences for research use. Read it before you repeat it: https://defianceinternational.io/studies
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Slightly older piglets (7–10 days old, 3.0–4.5 kg, males and females) were subjected to HI (n = 21) and sham (n = 6) procedures for neuropathology outcomes and scalp EEG recordings with survival of 4 days.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
In this preclinical study, we investigated the efficacy and safety of HNG in preventing GC-induced growth retardation and osteoporosis in mouse models of DMD.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Serum humanin concentrations were significantly elevated in breast cancer patients compared with healthy controls (p < 0.001).
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Humanin displayed a curvilinear association with CVMM, with both low (<462 pg/mL) and high (>778 pg/mL) levels linked to an increased risk.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Proceedings of the National Academy of Sciences of the United States of America · 2025
Study scale: It works as follows: The input image is distributed into N (flattened 2D) patches (where we keep N = 6 for the MNIST experiments), and linear embeddings of these patches are fed as input to the encoder of the trained ViT.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
Not reported in the declared source.
Study scale
It works as follows: The input image is distributed into N (flattened 2D) patches (where we keep N = 6 for the MNIST experiments), and linear embeddings of these patches are fed as input to the encoder of the trained ViT.
Intervention or exposure
Not reported in the declared source.
Comparator
Not reported in the declared source.
Outcomes examined
By parametrically varying synaptic conductances within physiologically realistic bounds, we quantified the distinct computational roles of each inhibitory subtype in shaping pyramidal output and circuit-level dynamics (Fig. 2 D and E).
Key findings
Hardware implementations demonstrated linear compute-time scaling with load, contrasting the quadratic scaling of simulations.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
In this study, we explored the hypothesis that delivery of ABE using novel self-assembling receptor targeted lipid nanoparticles (RTN) and conversion of G542X to G542R could lead to a therapeutically functional treatment.
Study design
Not reported in the declared source.
Participants or experimental system
We used an adenine base editor (ABE8e Cas9) and guide RNA (sgRNA)/enhanced green fluorescent protein (EGFP) plasmids encapsulated in receptor targeted nanoparticles (RTN), delivered to Bmi-1 transduced basal human CF airway epithelial cells harbouring the homozygous CFTR G542X variant, to convert the stop codon to G542R, a variant which is amenable to modulator therapy.
Study scale
(n = 3) using OdysseyCLx fluorescence data.
Intervention or exposure
Treatment with ETI was performed 24 h prior to functional assessment with 1 μM VX-445, 3 μM VX-661, and 1 μM VX-770.
Comparator
Treatment with IL-1β was used as a positive control.
Outcomes examined
We assessed editing efficiency of ABE delivered as plasmid DNA also encoding EGFP, by RTN to CFTR G542X homozygous airway epithelial cells.
Key findings
In cells differentiated at air–liquid-interface (ALI), 17% and 52% editing of CFTR G542X increased mRNA abundance.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Since both exercise and AST can potentially impact HN and certain microRNAs that regulate OS and IF, our study aimed to explore how the combination of CT and AST affects these processes.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Given the indispensable role of SCN VIP neurons in maintaining circadian rhythm (5), we examined here the effect of mitofusin 2 (Mfn2), a mitochondrial membrane protein involved in the control of the fusion process (19), on SCN VIP neuronal activity and downstream effects on behavior, thermoregulation, and sleep.
Study design
To visualize VIP neurons, Cre-dependent tdTomato reporter control Ai14 mice (Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J; strain JAX:007914) crossed with Mfn2–/– mice were used for histological analysis and ex vivo electrophysiological recordings at the age of 1.5–3 months.
Participants or experimental system
To determine the effect of the SCN circadian oscillation in the LD cycle at the cellular level, we first analyzed synapse density and mitochondrial morphology in SCN core VIP- expressing neurons of C57BL/6J mice at Zeitgeber times (ZT) 1, 7, 13, 19, (ZT0: lights on; ZT12: lights off).
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Compared with the control animals, they had shifted activity onset toward the light phase, resulting in higher activity counts during the light phase and statistically lower activity counts during the dark phase, but without changes in their total activity level (Figure 4, D and E).
Outcomes examined
Along with mitochondria modifications in SCN VIP neurons of Mfn2–/– mice, we analyzed daily rearrangements of the number of synapses in these neurons.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Here, we tested whether GluN2C/D‐containing NMDARs mediate NMDAR currents in the IC, as well as the role of these receptors in synaptic integration and sound processing.
Study design
The signal was developed using the horseradish peroxidase for each channel and then opal dyes diluted at 1:1000 were assigned for each channel: tdTomato was assigned to Opal 690 (catalog. no. FP1497001KT; Akoya Bioscience, Marlborough, MA, USA), Glun2c was assigned to Opal 570 (catalog. no. FP1488001KT; Akoya Bioscience), and Glun2d was assigned to Opal 520 (catalog. no. FP1487001KT; Akoya Bioscience).
Participants or experimental system
Animals were kept under a 12:12 h light/dark photocycle with food and water available ad libitum.
Study scale
Male (n = 18) and female (n = 15) mice aged P30–P66 were used.
Intervention or exposure
Recording pipettes were pulled from borosilicate glass capillaries (outer diameter 1.5 mm, inner diameter 0.86 mm; Sutter Instrument) with a P‐1000 microelectrode puller (Sutter Instrument) and filled with an internal solution containing (in mm): 115 CsOH, 115 d‐gluconic acid, 7.76 CsCl, 0.5 EGTA, 10 HEPES, 10 Na2 phosphocreatine, 4 MgATP and 0.3 NaGTP, supplemented with 0.1% biocytin (w/v), pH adjusted to 7.4 with CsOH and osmolality to 290 mosmol kg–1 with sucrose.
Comparator
To test for vehicle effects, we performed control experiments where puff‐elicited EPSCs were compared between control and DMSO (vehicle) conditions.
Outcomes examined
Co‐localization of Glun2c and Glun2d in tdTomato‐positive neurons was quantified manually using Neurolucida 360 (MBF Bioscience, Williston, VT, USA).
Key findings
Here, we report the widespread expression of Glun2c and Glun2d mRNA in IC neurons.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
To test epitalon on primary cells, IBR.3 was treated with 1 μg/ml for four days.
Study design
There were several limitations of our work, the main one being that this was an in vitro study using human cell lines in 2D cell cultures.
Participants or experimental system
Human 21NT breast cancer cells were cultured in 1 × Modified Eagle’s medium alpha (alpha MEM) (Gibco), 2.8 μM hydrocortisone, 1 μg/ml insulin, 10% foetal calf serum (FCS), 1% gluta- max, 10 mM HEPES, 0.1 mM NEAA and 12.5 ng/ml Epithelial Growth Factor (EGF).
Study scale
Not reported in the declared source.
Intervention or exposure
Breast cancer cells (21NT and BT474) were treated daily with (0.1, 0.2, 0.5, and 1.0 μg/mL) of epitalon for 4 days.
Comparator
Untreated cells were included to serve as a baseline control.
Outcomes examined
Protein from the 21NT, BT474, HMEC and IBR.3 cells were extracted using the TRAPeze 1 × CHAPS lysis buffer (S7705, Millipore) and quantified using the CB-X protein assay kit (G-Bioscience).
Key findings
In this article, the breast cancer cell lines 21NT, BT474, and normal epithelial and fibroblast cells were treated with epitalon then DNA, RNA, and proteins were extracted. qPCR and Immunofluorescence analysis demonstrated dose-dependent telomere length extension in normal cells through hTERT and telomerase upregulation.
Limitations and uncertainty
It is important to note that the qPCR method used measures average telomere lengths across all chromosomes, which represents a limitation of the actual technique.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: This boosting of sensory responses did not occur when the prior trial was a Miss to the same whisker, or > 1 Hit to a different whisker (Fig. 4D, E, n = 6 mice, 70 sessions, 6906 PYR cells, 4–19 sessions per mouse, 118.7 ± 5.96 cells (range: 3–213) per session).
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Here, we developed an experimental model of focal attention based on reward history in the mouse whisker tactile system and used it to investigate the neurobiological basis of attention in the sensory cortex.
Study design
Not reported in the declared source.
Participants or experimental system
We studied attentional behavior in head-fixed mice during a Go/NoGo whisker touch detection task, which included Go stimuli on many different whiskers.
Study scale
This boosting of sensory responses did not occur when the prior trial was a Miss to the same whisker, or > 1 Hit to a different whisker (Fig. 4D, E, n = 6 mice, 70 sessions, 6906 PYR cells, 4–19 sessions per mouse, 118.7 ± 5.96 cells (range: 3–213) per session).
Intervention or exposure
To motivate behavioral training, each mouse received 0.8–1.5 mL of water daily, calibrated to maintain 85% of pre-training body weight.
Comparator
When the prior trial was a NoGo, mice detected the current Go whisker with d’ = 1.13 ± 0.02 (termed d’NoGo, mean ± SEM across 476 sessions, 22 mice), which we consider baseline detection sensitivity. d’ for detecting a given Go whisker was elevated following 1 prior Hit to the same whisker, and even more so following multiple consecutive Hits to the same whisker (d’>1HitSame = 2.45 ± 0.11, p = 1.0e-4 vs d’NoGo, permutation test).
Outcomes examined
Expert mice effectively distinguished Go from NoGo trials, quantified by d’ from signal detection theory (Supplementary Fig. S1A).
Key findings
Prior Hits to the same whisker (maroon) increased d’ for detecting that whisker on the current trial (‘attend toward’), while prior Hits to a different whisker (yellow) decreased d’ (‘attend away’).
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
The ESCAS study was an exploratory, prospective, randomized-controlled, double-blinded, academic study designed to assess the efficacy and safety of Cerebrolysin in combination with speech therapy compared with a placebo (saline solution) in combination with speech therapy for the treatment of nonfluent aphasia following acute ischemic stroke.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked